Provention Bio Operating Income

As of the most recent data (December 2022), PRVB shows a operating income of $-130M. That compares with $-120M in the prior-year period — down 10.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PRVB's operating income is now $-130M (was $-120M) — a 10.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Provention Bio is outperforming or lagging.

Tracking PRVB's operating income over time shows whether Provention Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $-130M That compares with $-120M in the prior-year period — down 10.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Provention Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-130M) with ownership activity and broader fundamentals.

Provention Bio's operating income is $-130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.